359 related articles for article (PubMed ID: 19450096)
1. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
2. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
4. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
[TBL] [Abstract][Full Text] [Related]
6. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
8. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
9. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
10. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
15. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
[TBL] [Abstract][Full Text] [Related]
16. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
[TBL] [Abstract][Full Text] [Related]
17. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trials with levosimendan.
Mebazaa A; Barraud D; Welschbillig S
Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]